Arun J. Sanyal
@arunjsanyalvcu
The views expressed here do not necessarily reflect those of VCU or its medical school or the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.
ID: 1689283345539031041
https://liverinstitute.medschool.vcu.edu 09-08-2023 14:32:12
253 Tweet
532 Followers
87 Following
Appreciate the coverage of Arun J. Sanyal work on survodutide by @AGA_GHIN.
.Arun J. Sanyal will discuss MASH and its consequences at the Economist Impact ISGlobal event.
"With the urgent unmet need of patients with +MASH, we hope that AIM-MASH can aid pathologists in the clinical trial setting.” --the paper's co-authors include director Arun J. Sanyal.
What an honour to have the world-renowned expert in #cirrhosis Jasmohan Bajaj to deliver this named lecture on #oral #gut #liver #axis in IDDF - International Digestive Disease Forum 2024! CUHK Medicine CUHK Gastroenterology & Hepatology Vincent Wong Terry Cheuk-Fung Yip Jimmy Che-To Lai
ICYMI! Participate in the first ALF #Liver Life Walk here in Richmond on Sat., Oct. 12. Donate or sign up to walk with team “UnStoppable VCU Liver” at liverlifewalk.org/virginia/ #LiverLifeWalk #UnStoppableVCULiver #LiverTwitter VCU Stravitz-Sanyal Institute for Liver Disease American Liver Foundation National
Happy to share our narrative review of the natural history of MASLD in The Lancet Gastroenterology & Hepatology Link: thelancet.com/journals/langa… Ying Shang Patrik Nasr Hannes Hegmar #LiverTwitter Karolinska Institutet
In The Lancet: GLP-1 receptor agonists, such as semaglutide, could curb both health & economic effects of obesity. In a Viewpoint, authors analyse GLP-1 receptor agonist coverage policies in 13 high-income countries to draw lessons for policy development: bit.ly/47gX2yz
Some very important research by our Jasmohan Bajaj that should give you pause to consider how we treat these patients.